Results 71 to 80 of about 4,378 (208)
Rapidly Growing ALK‐Negative NTRK3‐Positive Inflammatory Myofibroblastic Tumour of the Lung
Respirology Case Reports, Volume 13, Issue 12, December 2025.This report describes the importance of comprehensive molecular testing in anaplastic lymphoma kinase‐negative inflammatory myofibroblastic tumour (IMT) and demonstrates that complete surgical resection can achieve excellent outcomes even in rapidly growing IMT.
Yukitaka Sato +5 more
wiley +1 more source
Blood Advances, 2020 : Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1 fusion oncogene.
Valentina Nardi +14 more
doaj +1 more source
Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report [PDF]
, 2022 Ramya Tadipatri +4 more
openalex +1 more source
The Journal of Pathology: Clinical Research, Volume 11, Issue 6, November 2025.Abstract Secretory breast carcinoma (SBC) is a rare tumour defined by ETV6‐NTRK3 rearrangement, but its clinicopathological spectrum and potential for aggressive behaviour remain incompletely characterised. We retrospectively reviewed 29 SBCs diagnosed between 2014 and 2024, including 28 females and one male aged 12–63 years (median 44).
Huayan Ren +9 more
wiley +1 more source
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
Communications Biology, 2020 Romel Somwar et al. find that cancer-causing NTRK gene fusions resistant to one form of inhibitor therapy can be resistant to other inhibitor types.
Romel Somwar +14 more
doaj +1 more source
OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation [PDF]
, 2020 Yaogeng Wang +5 more
openalex +1 more source
Head &Neck, Volume 47, Issue 11, Page E116-E121, November 2025.ABSTRACT Background The NTRK fusion gene is detected in most salivary gland secretory carcinomas. While tropomyosin receptor kinase (TRK) inhibitors are used for various solid tumors with the fusion gene, there are no reports regarding TRK inhibitor use for unresectable parotid gland carcinomas that subsequently shrink and become resectable.
Arisa Nagano +11 more
wiley +1 more source
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer [PDF]
, 2020 Joshua A. Roth +4 more
openalex +1 more source
Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management
MedComm, Volume 6, Issue 11, November 2025.Thyroid cancer risk is influenced by both genetic and modifiable factors, including mutations, radiation exposure, lifestyle, and pre‐existing benign conditions. Diagnosis involves physical exams, ultrasound, scintigraphy, laboratory tests, and fine‐needle aspiration biopsy (FNAB).
Yu‐Dong Li +3 more
wiley +1 more source
United European Gastroenterology Journal, Volume 13, Issue 9, Page 1678-1689, November 2025.ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, mainly due to its aggressive nature, early metastasis, diagnosis at late stages, and limited response to systemic anticancer therapy. Perineural invasion (PNI), defined as the infiltration of neoplastic cells along nerve fibers and within nerve sheaths, is ...
Martin Lovecek +10 more
wiley +1 more source